HOW IS OLEPTRO DOING??

Quote
It is open positions from people jumping ship already! I do not think the contract will last much longer. The numbers are terrible and nothing positive being said lately about the contract.
 












Anonymous said:
You can believe anything you want. The existing market share data since launch shows that it's not doing well.
Click to expand...

I wouldn't know the existing market share data, and it isn't productive to dismiss the opinion you've given (actually, I appreciate it), but since we're looking at only 4-5 months of promotion of a med that is most likely running up against it's share of stumbling blocks, I'll hold on to my optimism a while longer. From comments mentioned so far, it does sound like Labo may have expectations that are considered lofty as opposed to realistic, but it wouldn't be the first time a drug in that class went from zero to hero, despite the results seen in it's first year.
 






Are you seeing any traction with the state medicaid programs? I noticed Oletpro is not listed on Fingertip Formulary-surprising since other drugs (Silenor) launched after Oleptro are listed.
 






Are you seeing any traction with the state medicaid programs? I noticed Oletpro is not listed on Fingertip Formulary-surprising since other drugs (Silenor) launched after Oleptro are listed.
 


































































Anonymous said:
Doesn't matter dipshit. At least 6 managers have left already!
Click to expand...


That's not the information I have, but in the unlikely event that you know something that I don't, you must also know that the weakest members occasionally have to get removed from the team.

I know this for certain, the 12/10 IMS data confirmed the October trend. With EOY due out in 2 weeks, we could really see the effort paying off.

Not everyone is cut out for this type of work. Maybe you are one of the guys that got let go last week? Jobs are hard to find these days. I can see why you are angry, but it's not the team's fault. They are doing a good job.
 






RE:Kate Holland Oleptro

Anonymous said:
The first full month of IMS data is available this morning and Oleptro is...let me look here...I'm still looking...hang on a second...be patient...Oh, I see the problem here. Not enough NRX volume to register.
Click to expand...

The reason that Oleptro has gone down the drain is Kate Holland. She is a total idiot with no sales knowledge. I am very surprised that we hired her after that screw up she made with Sonta. Send Kate Holland Packing before she kills Oleptro like she killed Sonata. The numbers do not lie. Kate Holland is a loser. Cut her loose please!!!!!
 






Yes, there is two regions!!! East and West. JP Brassil is the regional manager for the East. Only 3 managers have left, 2 from the East and 1 from the West. Go on Quintiles website and there are job openings for contract 6385(Angelini-Labopharm). People are LEAVING not getting fired. That is so stupid.......the drug STINKS!!!!!!
 












My honest prediction is that after 1 year (July) Angelini Labopharm does 1 of 2 things:

1) adds another product that we could sell alongside Oleptro but doesn't compete with Oleptro

2) cancels the contract with NQ and has another salesforce with current access to psychs sell Oleptro. The Solvay salesteam that Wyeth bought comes to mind. They've already sold Luvox CR for a couple years and since it's only indicated for Social anxiety and OCD it technically doesn't compete with Oleptro.

Not wishing anyone to loose their job, I'm just saying from a business sense I don't see how they can afford to continue at the current rx trend level with our salesforce.
 






Top Bottom
Back
Quote